(Q42175503)

English

Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy

scientific article published on 6 January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

19

object named as

Namiki Izumi

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

author name string

Jun Itakura

1

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Masayuki Kurosaki

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Hitomi Takada

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Natsuko Nakakuki

4

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Syuya Matsuda

5

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Kouichi Gondou

6

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Yu Asano

7

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Nobuhiro Hattori

8

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Yoshie Itakura

9

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Nobuharu Tamaki

10

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Yutaka Yasui

11

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Shoko Suzuki

12

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Takanori Hosokawa

13

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Kaoru Tsuchiya

14

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Hiroyuki Nakanishi

15

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Yuka Takahashi

16

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Syinya Maekawa

17

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Nobuyuki Enomoto

18

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

publication date

6 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Hepatology Research

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

E115-21

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

New horizons in hepatitis C antiviral therapy with direct-acting antivirals.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Antiviral treatment of hepatitis C virus infection and factors affecting efficacy

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Hepatitis C virus resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Resistance to direct antiviral agents in patients with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

IL28B single nucleotide polymorphisms in the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

IL28B and the control of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Efficacy of daclatasvir in hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Hepatitis C virus NS5A inhibitors and drug resistance mutations

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Antiviral therapy of hepatitis C in 2014: do we need resistance testing?

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12474

21 January 2018

Identifiers

10.1111/HEPR.12474

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42175503&oldid=1935335802"